GHK-Cu (Copper Peptide) vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →Side-by-Side Comparison
| Aspect | GHK-Cu (Copper Peptide) | Semaglutide |
|---|---|---|
| Mechanism | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. |
| Typical Dosage | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. |
| Administration | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. |
| Side Effects | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. |
| Best For |